Amgen Says Top-Line Results from Phase 3 Aranesp RED-HF Trial Did Not Meet Primary Endpoint
Posted on January 16, 2013 at 16:18 PM EST
Amgen (NASDAQ: AMGN ) today announced top-line results of the Phase 3 Aranesp^® (darbepoetin alfa) RED-HF^® (Reduction of Events With Darbepoetin Alfa in Heart Failure) Trial. The trial was initiated in 2006, and a total of 2,278 patients with symptomatic systolic heart failure and anemia (hemoglobin levels ranging from 9.0-12.0 g/dL) were randomized to